T
Thomas Karagiannis
Researcher at Aristotle University of Thessaloniki
Publications - 41
Citations - 2456
Thomas Karagiannis is an academic researcher from Aristotle University of Thessaloniki. The author has contributed to research in topics: Type 2 diabetes & Metformin. The author has an hindex of 16, co-authored 39 publications receiving 1911 citations. Previous affiliations of Thomas Karagiannis include University of Oxford.
Papers
More filters
Journal ArticleDOI
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Despoina Vasilakou,Thomas Karagiannis,Eleni Athanasiadou,Maria Mainou,Aris Liakos,Eleni Bekiari,Maria Sarigianni,David R. Matthews,Apostolos Tsapas +8 more
TL;DR: Sodium-glucose cotransporter 2 inhibitors may improve short-term outcomes in adults with type 2 diabetes, but effects on long- term outcomes and safety are unclear.
Journal ArticleDOI
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis
Thomas Karagiannis,Paschalis Paschos,Konstantinos Paletas,David R. Matthews,Apostolos Tsapas +4 more
TL;DR: In patients with type 2 diabetes who do not achieve the glycaemic targets with metformin alone, DPP-4 inhibitors can lower HbA1c in a similar way to sulfonylureas or pioglitazone, with neutral effects on body weight.
Journal ArticleDOI
Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis
Eleni Bekiari,Konstantinos Kitsios,Hood Thabit,Martin Tauschmann,Eleni Athanasiadou,Thomas Karagiannis,Anna-Bettina Haidich,Roman Hovorka,Apostolos Tsapas +8 more
TL;DR: Artificial pancreas systems are an efficacious and safe approach for treating outpatients with type 1 diabetes and were consistent in a subgroup analysis both for single hormone and dual hormone artificial pancrea systems.
Journal ArticleDOI
Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.
Aris Liakos,Thomas Karagiannis,Eleni Athanasiadou,Maria Sarigianni,Maria Mainou,Konstantinos Papatheodorou,Konstantinos Papatheodorou,Eleni Bekiari,Apostolos Tsapas,Apostolos Tsapas +9 more
TL;DR: The objective was to assess the efficacy and safety of the novel sodium‐glucose cotransporter 2 (SGLT2) inhibitor empagliflozin compared with placebo or other antidiabetic agents in patients with type 2 diabetes.
Journal ArticleDOI
Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
Apostolos Tsapas,Ioannis Avgerinos,Thomas Karagiannis,Konstantinos Malandris,Apostolos Manolopoulos,Panagiotis Andreadis,Aris Liakos,David R. Matthews,Eleni Bekiari +8 more
TL;DR: In diabetic patients at low cardiovascular risk, no treatment differs from placebo for vascular outcomes, and in patients at increased cardiovascular risk receiving metformin-based background therapy, specific GLP-1 RAs and SGLT-2 inhibitors have a favorable effect on certain cardiovascular outcomes.